144 related articles for article (PubMed ID: 14718607)
1. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir.
Mouly SJ; Paine MF; Watkins PB
J Pharmacol Exp Ther; 2004 Mar; 308(3):941-8. PubMed ID: 14718607
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
Eagling VA; Profit L; Back DJ
Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
[TBL] [Abstract][Full Text] [Related]
3. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion.
Paine MF; Leung LY; Lim HK; Liao K; Oganesian A; Zhang MY; Thummel KE; Watkins PB
J Pharmacol Exp Ther; 2002 Apr; 301(1):174-86. PubMed ID: 11907172
[TBL] [Abstract][Full Text] [Related]
5. First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers.
Fisher JM; Wrighton SA; Watkins PB; Schmiedlin-Ren P; Calamia JC; Shen DD; Kunze KL; Thummel KE
J Pharmacol Exp Ther; 1999 May; 289(2):1134-42. PubMed ID: 10215697
[TBL] [Abstract][Full Text] [Related]
6. New insights into drug absorption: studies with sirolimus.
Paine MF; Leung LY; Watkins PB
Ther Drug Monit; 2004 Oct; 26(5):463-7. PubMed ID: 15385826
[TBL] [Abstract][Full Text] [Related]
7. A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells.
Patel J; Hussain A; Pal D; Mitra AK
Am J Ther; 2004; 11(2):114-23. PubMed ID: 14999363
[TBL] [Abstract][Full Text] [Related]
8. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
Berginc K; Trdan T; Trontelj J; Kristl A
Biopharm Drug Dispos; 2010 Nov; 31(8-9):495-505. PubMed ID: 21104925
[TBL] [Abstract][Full Text] [Related]
9. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
10. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Cummins CL; Jacobsen W; Benet LZ
J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
[TBL] [Abstract][Full Text] [Related]
11. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate.
Cummins CL; Mangravite LM; Benet LZ
Pharm Res; 2001 Aug; 18(8):1102-9. PubMed ID: 11587480
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
13. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism.
Huang J; Si L; Jiang L; Fan Z; Qiu J; Li G
Int J Pharm; 2008 May; 356(1-2):351-3. PubMed ID: 18242899
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
Ieiri I; Tsunemitsu S; Maeda K; Ando Y; Izumi N; Kimura M; Yamane N; Okuzono T; Morishita M; Kotani N; Kanda E; Deguchi M; Matsuguma K; Matsuki S; Hirota T; Irie S; Kusuhara H; Sugiyama Y
J Clin Pharmacol; 2013 Jun; 53(6):654-61. PubMed ID: 23381882
[TBL] [Abstract][Full Text] [Related]
15. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.
Hochman JH; Chiba M; Nishime J; Yamazaki M; Lin JH
J Pharmacol Exp Ther; 2000 Jan; 292(1):310-8. PubMed ID: 10604964
[TBL] [Abstract][Full Text] [Related]
16. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes.
Benet LZ; Cummins CL; Wu CY
Int J Pharm; 2004 Jun; 277(1-2):3-9. PubMed ID: 15158963
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
Katoh M; Nakajima M; Yamazaki H; Yokoi T
Eur J Pharm Sci; 2001 Feb; 12(4):505-13. PubMed ID: 11231118
[TBL] [Abstract][Full Text] [Related]
18. Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells.
Gibbs MA; Baillie MT; Shen DD; Kunze KL; Thummel KE
Pharm Res; 2000 Mar; 17(3):299-305. PubMed ID: 10801218
[TBL] [Abstract][Full Text] [Related]
19. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
20. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
Fitzsimmons ME; Collins JM
Drug Metab Dispos; 1997 Feb; 25(2):256-66. PubMed ID: 9029057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
